JHOP - April 2020 Vol 10, No 2

Original Article

From the Literature

GU Cancers Symposium Highlights

GI Cancers Symposium Highlights

Symptom Management Overview

Rapid Onset of Severe Transaminitis in a Patient with Non–Small-Cell Lung Cancer After First Dose of Nivolumab 480 mg

Matthew Stankowicz, PharmD, BS; Megan Banaszynski, PharmD, BCOP; Russell Crawford, RPh, BCOP

Original Article

Clinical Outcomes Using Carboplatin Desensitizations in Patients with Gynecologic Cancer

Eris Tollkuci, PharmD, BCOP; Anna Chalmers, MD; Kathryn Schultz, PharmD, BCPS, BCOP; Sanjib Basu, PhD; Summer Dewdney, MD; Lydia Usha, MD

Extended versus Intermittent Infusions of Piperacillin-Tazobactam in Patients with Febrile Neutropenia

Daniel J. Przybylski, PharmD; David J. Reeves, PharmD, BCOP

Reduction in Utilization and Costs Associated with Formulary Restrictions of Injectable Calcitonin

Robert Walchack, PharmD, BCOP; Jordan Hill, PharmD, BCOP; Sijin Wen, PhD; Aaron Cumpston, PharmD, BCOP

From the Literature

Adding Tucatinib to Trastuzumab and Capecitabine Improves Survival in HER2-Positive Metastatic Breast Cancer

Trastuzumab Deruxtecan Shows Durable Antitumor Activity in HER2-Positive Metastatic Breast Cancer

First-Line Osimertinib Therapy Boosts Overall Survival in Non–Small-Cell Lung Cancer

GU Cancers Symposium Highlights

Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma

First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma

GI Cancers Symposium Highlights

Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation

Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation

Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer

AVBCC Webcast Highlights: COVID-19 Impact on the Cancer Care Delivery Ecosystem

Symptom Management Overview

Prevention of Chemotherapy-Induced Nausea and Vomiting in Adult Patients Undergoing Hematopoietic Stem-Cell Transplant: Is Olanzapine an Option?

By Ariel Denson, PharmD; Alyshia Wiggins, PharmD; Allison Martin, PharmD, BCOP; Justin Arnall, PharmD, BCOP, CPP

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.